Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) has successfully closed its initial public offering, selling 2,875,000 shares at $6.00 each, including an option for underwriters to purchase 375,000 additional shares. The offering generated approximately $14.8 million in net proceeds for the company. The SEC declared the registration statement effective on June 24, 2021. Acurx focuses on developing new antibiotics targeting difficult-to-treat bacterial infections.
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) announced the pricing of an underwritten initial public offering of 2,500,000 shares at $6.00 per share, aiming to raise approximately $15 million. The offering includes a 45-day option for underwriters to purchase an additional 375,000 shares. The proceeds will fund a Phase 2b clinical trial for ibezapolstat and pre-clinical development of ACX-375C, alongside general corporate purposes. Trading is set to begin on June 25, 2021, with the closing expected on June 29, 2021, subject to customary conditions.